Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jop Mostert

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populationsEline Me Coerver, Sezgi Kaçar, Olga Ciccarelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 11, 2014
MRI pattern in asymptomatic natalizumab-associated PMLMike P Wattjes, Anke Vennegoor, Martijn D Steenwijk, et al.
Journal of Medical Economics|May 23, 2013
Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The NetherlandsKorinna Karampampa, Anders Gustavsson, Erik Th L van Munster, et al.
Disability and Rehabilitation|November 9, 2019
A Dutch validation study of the Multiple Sclerosis Work Difficulties Questionnaire in relapsing remitting multiple sclerosisElianne van Egmond, Dennis van Gorp, Cynthia Honan, et al.
Journal of Neurology|May 7, 2026
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosisDaan J de Jong, Pam C G Molenaar, Vera Verhoef, et al.
Trials|January 28, 2014
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trialMelissa Cambron, Jop Mostert, Patrick Haentjens, et al.
JAMA Neurology|December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical TrialEline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populationsEline Me Coerver, Sezgi Kaçar, Olga Ciccarelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 11, 2014
MRI pattern in asymptomatic natalizumab-associated PMLMike P Wattjes, Anke Vennegoor, Martijn D Steenwijk, et al.
Journal of Medical Economics|May 23, 2013
Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The NetherlandsKorinna Karampampa, Anders Gustavsson, Erik Th L van Munster, et al.
Disability and Rehabilitation|November 9, 2019
A Dutch validation study of the Multiple Sclerosis Work Difficulties Questionnaire in relapsing remitting multiple sclerosisElianne van Egmond, Dennis van Gorp, Cynthia Honan, et al.
Journal of Neurology|May 7, 2026
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosisDaan J de Jong, Pam C G Molenaar, Vera Verhoef, et al.
Trials|January 28, 2014
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trialMelissa Cambron, Jop Mostert, Patrick Haentjens, et al.
JAMA Neurology|December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical TrialEline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Pageof 5